Literature DB >> 23233226

Computational analysis of deleterious missense mutations in aspartoacylase that cause Canavan's disease.

K Sreevishnupriya1, P Chandrasekaran, A Senthilkumar, R Sethumadhavan, V Shanthi, P Daisy, J Nisha, K Ramanathan, R Rajasekaran.   

Abstract

In this work, the most detrimental missense mutations of aspartoacylase that cause Canavan's disease were identified computationally and the substrate binding efficiencies of those missense mutations were analyzed. Out of 30 missense mutations, I-Mutant 2.0, SIFT and PolyPhen programs identified 22 variants that were less stable, deleterious and damaging respectively. Subsequently, modeling of these 22 variants was performed to understand the change in their conformations with respect to the native aspartoacylase by computing their root mean squared deviation (RMSD). Furthermore, the native protein and the 22 mutants were docked with the substrate NAA (N-Acetyl-Aspartic acid) to explain the substrate binding efficiencies of those detrimental missense mutations. Among the 22 mutants, the docking studies identified that 15 mutants caused lower binding affinity for NAA than the native protein. Finally, normal mode analysis determined that the loss of binding affinity of these 15 mutants was caused by altered flexibility in the amino acids that bind to NAA compared with the native protein. Thus, the present study showed that the majority of the substrate-binding amino acids in those 15 mutants displayed loss of flexibility, which could be the theoretical explanation of decreased binding affinity between the mutant aspartoacylases and NAA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233226     DOI: 10.1007/s11427-012-4406-8

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  1 in total

1.  Comprehensive Computational Analysis of Protein Phenotype Changes Due to Plausible Deleterious Variants of Human SPTLC1 Gene.

Authors:  Tayyaba Sadaf; Peter John; Attya Bhatti
Journal:  Int J Mol Cell Med       Date:  2019-04-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.